Tolosa E, Blesa R, Bayes A, Forcadell F
Neurology Service, Hospital Clinico y Provincial, Barcelona, Spain.
Clin Neuropharmacol. 1987 Apr;10(2):168-74.
The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disability Scale and Columbia University Rating Scale scores were significantly reduced during bromocriptine therapy, when compared with either baseline or placebo scores. Two patients improved greater than 50% and had no side effects. Transient side effects appeared in four patients. Bromocriptine at doses of 20 mg/day or below may yield effective symptomatic improvement in de novo parkinsonism and may be considered as the initial treatment in young parkinsonian patients with only mild-to-moderate disability.
对15名轻度至中度残疾、此前未接受过左旋多巴治疗的帕金森病患者，采用单盲方式并设置安慰剂阶段，研究了每日剂量高达20毫克的溴隐亭的效果。对于完成9个月试验的11名患者，与基线或安慰剂评分相比，在溴隐亭治疗期间，西北大学残疾量表和哥伦比亚大学评定量表的评分均显著降低。两名患者改善超过50%且无副作用。四名患者出现短暂副作用。每日剂量20毫克及以下的溴隐亭可能对初发帕金森病产生有效的症状改善，可被视为仅患有轻度至中度残疾的年轻帕金森病患者的初始治疗方法。
